Neda Hashemi, MD, is a triple board-certified medical oncologist and hematologist. Dr. Hashemi earned her medical degree from Iran University of Medical Sciences in Tehran. She went on to complete a neuro-oncology research fellowship at Cleveland Clinic, followed by internal medicine residency at the University of Texas Health Science Center in Houston, where she was honored as the Outstanding Graduating Resident of the Year. Her training continued at Indiana University, where she completed her hematology/oncology fellowship and served as chief fellow.
Prior to joining Ironwood, Dr. Hashemi was a faculty member and Associate Professor at the University of New Mexico Comprehensive Cancer Center. There, she led the Genitourinary Working Group and helped launch the center’s Prostate Cancer Theranostic Program. She also served as Medical Director of the New Mexico Cancer Research Alliance and chaired the center’s Protocol Review and Monitoring Committee. Nationally, she contributed to research as the Community Representative of the National Cancer Institute’s Prostate Cancer Task Force.
Dr. Hashemi has served as a site principal investigator on numerous clinical trials and has authored peer-reviewed publications in leading journals. She is a frequent invited speaker at regional conferences in oncology and urology.
Dr. Hashemi specializes in genitourinary and lung, head & neck cancers, including cancers of the prostate, kidney, bladder, testis, penis, lung, oral, nasal cavity, and thyroid. She brings a deep commitment to personalized, compassionate care and advanced cancer treatment to Ironwood Cancer Research Centers. Her philosophy of care centers on treating the whole person—not just the disease. She is deeply honored to walk alongside her patients through their cancer journey, offering both cutting-edge therapies and heartfelt support.
Medical Oncologist & Hematologist
| Somatic genomic landscape of prostate adenocarcinoma at a comprehensive cancer center in New Mexico: A retrospective study (2015-2022).
M Abdelsamia, DJ Chavarin, J Coy, VS Pankratz, B Tawfik, … Journal of Clinical Oncology 43 (5_suppl), 200-200 |
| Geographic variations in corporate sponsorship for cancer center charity events.
MW Shilling, N Hashemi-Sadraei, SK Shah Journal of Clinical Oncology 42 (16_suppl), e23116-e23116 |
| PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)
R Aggarwal, G Heller, DW Hillman, H Xiao, J Picus, ME Taplin, T Dorff, … Journal of Clinical Oncology 42 (10), 1114-1123 |
| Duodenal duplication cyst masquerading as metastatic nonseminomatous germ cell tumor
LS Faber, H Hodges, N Hashemi-Sadraei, FM Alba JU Open Plus 2 (3), e00017 |
| Racial and ethnic differences in the receipt of metabolic syndrome risk factor screening and treatment among individuals with prostate cancer treated with androgen deprivation …
YK Barqawi, ME Borrego, MH Roberts, T Thompson, N Hashemi-Sadraei Journal of Clinical Oncology 42 (4_suppl), 29-29 |
| Nephrotoxicity in the age of immune checkpoint inhibitors: mechanisms, diagnosis, and management
K Moturi, H Sharma, N Hashemi-Sadraei International Journal of Molecular Sciences 25 (1), 414 |
| Impact of audio-visual tool on patient comfort level at a comprehensive cancer center infusion suite: Preliminary results.
A Cheeti, N Hashemi-Sadraei, C Okino, A Cox, R Kittson, B Tawfik, … JCO Oncology Practice 19 (11_suppl), 348-348 |
| Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control
H Sharma, KR Moturi, VS Pankratz, E Yilmaz, OB Gbolahan, A Kumar, … Journal of Cancer Research and Clinical Oncology 149 (11), 8673-8680 |
| HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer.
J Brown, HZ Kaimakliotis, WK Kelly, V Ammons, J Picus, R Walling, … Journal of Clinical Oncology 41 (6_suppl), 448-448 |
| Time to treatment initiation and its impact on real‐world survival in metastatic colorectal cancer and pancreatic cancer
O Gbolahan, N Hashemi‐Sadraei, S Yash, G Williams, R Ramachandran, … Cancer Medicine 12 (3), 3488-3498 |
| Cutaneous metastasis from prostate cancer: a case report with literature review
H Sharma, M Franklin, R Braunberger, N Hashemi-Sadraei Current Problems in Cancer: Case Reports 7, 100175 |
| Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control.
H Sharma, KR Moturi, E Yilmaz, OB Gbolahan, A Kumar, … Journal of Clinical Oncology 40 (16_suppl), 2586-2586 |
| Improving outpatient infusion clinic wait times at a comprehensive cancer center
N Hashemi-Sadraei, S Sasankan, N Crozier, B Tawfik, R Kittson, … JCO Oncology Practice 17 (12), e1935-e1942 |
| Impact of time to treatment initiation on real-world (RW) outcomes in metastatic pancreatic cancer (mPC) in the United States.
OB Gbolahan, DA Outlaw, N Hashemi, RK Paluri, GR Williams Journal of Clinical Oncology 39 (15_suppl), e16254-e16254 |
| Impact of time to treatment initiation on real-world (RW) outcomes in metastatic colorectal cancer (mCRC) in the United States.
OB Gbolahan, DA Outlaw, N Hashemi, RK Paluri, GR Williams Journal of Clinical Oncology 39 (15_suppl), 3595-3595 |
| Pharmacist-driven oral oncolytic medication education and consent
H Bowles, B Tawfik, J Abernathy, R Lauer, N Hashemi, Z Dayao JCO Oncology Practice 16 (10), e1209-e1215 |
| Plant-based diet trends in oncology patients.
BR Webster, MV Ton-That, N Hashemi-Sadraei, SK Shah Journal of Clinical Oncology 38 (15_suppl), e19224-e19224 |
| Oral oncolytic education and adherence monitoring in poor, rural and minority patients.
T Menhorn, A Zarick-Jones, M Harari Turquie, S Sasankan, … Journal of Clinical Oncology 38 (15_suppl), e19212-e19212 |
| Optimizing infusion wait time: Redesigning medication order verification/approval at a comprehensive cancer center.
N Hashemi-Sadraei, ZR Dayao, S Sasankan, A Cox, S Peacock, … Journal of Clinical Oncology 38 (15_suppl), e14042-e14042 |
| Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma …
N Adra, RJ Hauke, HZ Kaimakliotis, S Gulati, N Hashemi, R Pili Journal of Clinical Oncology 38 (6_suppl), TPS587-TPS587 |
| NAD (P) H: Quinone oxidoreductase (NQO1) and catalase expression in nonseminomatous germ cell tumors.
N Hashemi-Sadraei, N Adra, KA Kessler, MT Idrees, L Einhorn, … Journal of Clinical Oncology 38 (6_suppl), 413-413 |
| Stop testing the patience of our patients–Optimizing workflow at a Cancer Center Infusion Suite
S Sasankan, Z Dayao, B Tawfik, A Cox, C Okino, S Peacock, J Abernathy, … |
| Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients
CM Perrino, J Eble, CS Kao, RD Whaley, L Cheng, M Idrees, … Human pathology 90, 27-36 |
| Prolonged response to anti–PD-1 antibody therapy in chemotherapy-refractory cholangiocarcinoma with high tumor mutational burden
O Gbolahan, N Hashemi-Sadraei, B O’Neil Journal of the National Comprehensive Cancer Network 17 (6), 644-648 |
| Improving communication with referring oncologists (RO): Indiana University experience.
N Hashemi-Sadraei, M Kalra, OB Gbolahan, AM Betbadal, S Grethlein Journal of Clinical Oncology 36 (30_suppl), 276-276 |
| Clinical characteristics of patients experiencing pathologic complete response following neoadjuvant therapy for borderline resectable/locally advanced pancreatic adenocarcinoma
N Hashemi-Sadraei, OB Gbolahan, H Salfity, B O’Neil, MG House, … American journal of clinical oncology 41 (10), 982-985 |
| Survival outcomes in plasmacytoid urothelial carcinoma: Results with contemporary systemic therapy.
N Hashemi-Sadraei, CM Perrino, MF Monn, E Bandali, L Cheng, M Idrees, … Journal of Clinical Oncology 36 (15_suppl), e16525-e16525 |
| Safety and tolerability of guadecitabine (SGI-110) plus cisplatin in patients (pts) with platinum-refractory germ cell tumors (GCT): Preliminary results from an open label …
N Hashemi-Sadraei, LH Einhorn, S Perkins, MJ Spinella, F Fang, … Journal of Clinical Oncology 36 (15_suppl), e16545-e16545 |
| Clinical features and survival outcomes in a prospective spontaneous regression (SR) protocol of renal cell carcinoma (RCC) and melanoma (M) patients.
OB Gbolahan, N Hashemi-Sadraei, A Conteh, HZ Kaimakliotis, W Storkus, … Journal of Clinical Oncology 36 (15_suppl), e16585-e16585 |
| Plasmacytoid urothelial carcinoma: A clinicopathological study.
N Hashemi-Sadraei, CM Perrino, MF Monn, E Bandali, L Cheng, M Idrees, … Journal of Clinical Oncology 36 (6_suppl), 482-482 |
| Targeting FGFR in squamous cell carcinoma of the lung
N Hashemi-Sadraei, N Hanna Targeted Oncology 12 (6), 741-755 |
| Do nonseminomatous germ cell tumors of the testis with lymphovascular invasion of the spermatic cord merit staging as pT3?
J Gordetsky, J Sanfrancesco, JI Epstein, K Trevino, H Xu, A Osunkoya, … The American Journal of Surgical Pathology 41 (10), 1397-1402 |
| The significance of lymphovascular invasion of the spermatic cord in the absence of cord soft tissue invasion
BC McCleskey, JI Epstein, C Albany, N Hashemi-Sadraei, MT Idrees, … Archives of Pathology and Laboratory Medicine 141 (6), 824-829 |
| Abstract B85: Pathologic complete response following systemic chemotherapy with or without chemoradiotherapy for borderline resectable/unresectable pancreatic adenocarcinoma …
N Hashemi-Sadraei, H Nguyen, B O’Neil, MG House, S Shahda Cancer Research 76 (24_Supplement), B85-B85 |
| Pathologic complete response following systemic chemotherapy with or without chemoradiotherapy for borderline resectable/unresectable pancreatic adenocarcinoma: Indiana …
N Hashemi-Sadraei, H Nguyen, B O’Neil, MG House, S Shahda CANCER RESEARCH 76 |
| Predictors of survival in patients with sarcoma admitted to the intensive care unit
R Gupta, N Heshami, C Jay, N Ramesh, J Song, X Lei, EJ Rose, K Carter, … Clinical sarcoma research 6 (1), 12 |
| Predictors of survival in patients with sarcoma admitted to the intensive care unit
RV 7. Gupta R, Hashemi-Sadraei N, Jay C, Ramesh N, Song J, Lei X, Rose EJ … Clin Sarcoma Res. 19 (6:12) |
| Treatment of cerebral radiation necrosis with bevacizumab: the Cleveland clinic experience
NH Sadraei, S Dahiya, ST Chao, ES Murphy, K Osei-Boateng, H Xie, … American journal of clinical oncology 38 (3), 304-310 |
| Abstract P5-10-09: Correlation between germline and tumor CYP450 2D6 gene polymorphisms
M Dehghani, AO Gonzalez, N Hashemi-Sadraei, S Zhang, KP Rosenblatt Cancer Research 75 (9_Supplement), P5-10-09-P5-10-09 |
| Adrenal Insufficiency Leading to Diagnosis of Metastatic Cancer
S Mallesara Sudhakar, N Hashemi-Sadraei, O Manlapaz, MY Yang, … Adrenal Insufficiency, THR-354-THR-354 |
| Long-term survivorship in patients (pts) with metastatic renal cell cancer (mRCC): A retrospective study from the MD Anderson Cancer Center (MDACC).
MT Campbell, AY Shah, N Hashemi, KD Nautiyal, PG Corn, LC Pagliaro, … Journal of Clinical Oncology 33 (7_suppl), 510-510 |
| Association of chronic co-morbidities with long term survival with metastatic renal cell carcinoma (mRCC).
MT Campbell, AY Shah, KD Nautiyal, N Hashemi, PG Corn, LC Pagliaro, … Journal of Clinical Oncology 33 (7_suppl), 472-472 |
| Long-term survivorship in patients with metastatic renal cell cancer (mRCC) managed with metastasectomy: A retrospective study from the MD Anderson Cancer Center (MDACC).
AY Shah, MT Campbell, KD Nautiyal, N Hashemi, SF Matin, … Journal of Clinical Oncology 33 (7_suppl), 504-504 |
| Epstein‐Barr virus‐related hemophagocytic lymphohistiocytosis: hematologic emergency in the critical care setting
N Hashemi-Sadraei, P Vejpongsa, M Baljevic, L Chen, M Idowu Case Reports in Hematology 2015 (1), 491567 |
| Lactic acidosis in gastric cancer
N Hashemi-Sadraei, JD Machicado, R Gupta, JA Huapaya Journal of gastrointestinal cancer 45 (Suppl 1), 192-194 |
| In-Hospital Outcomes in Patients With a Malignancy Admitted for Acute Pancreatitis: 1513
T Jana, J Machicado, S Batra, N Hashemi-Sadraei, S Guha Official journal of the American College of Gastroenterology| ACG 109, S667 |
| Bilateral Acromioclavicular Septic Arthritis as an Initial Presentation of Streptococcus pneumoniae Endocarditis
N Hashemi-Sadraei, R Gupta, JD Machicado, R Govindu Case reports in infectious diseases 2014 (1), 313056 |
| Risk factors for venous thromboembolism in elderly patients with glioblastoma.
N Hashemi-Sadraei, R Sharif, J Machicado, S Dahiya, MS Ahluwalia Journal of Clinical Oncology 31 (15_suppl), e13031-e13031 |
| Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges
G Rahmathulla, EJ Hovey, N Hashemi-Sadraei, MS Ahluwalia OncoTargets and therapy, 371-389 |
| Idiopathic pulmonary fibrosis in a referral center in Iran: are patients developing the disease at a younger age?
NH Sadraei, T Riahi, MR Masjedi Archives of Iranian medicine 16 (3), 0-0 |
| Cerebrovascular Events in Glioma Patients Treated with Bevacizumab (P07. 013)
D Patel, S John, N Hashemi-Sadraei, M Ahluwalia Neurology 80 (7_supplement), P07. 013-P07. 013 |
| Abstract TP217: Cerebrovascular Events in Glioma Patients Treated with Bevacizumab
DK Patel, S John, N Hashemi-Sadraei, M Ahluwalia Stroke 44 (suppl_1), ATP217-ATP217 |
| Adult low-grade gliomas: The Cleveland Clinic experience.
L Robles Irizarry, AA Fawole, N Hashemi-Sadraei, M Patel, P Elson, … Journal of Clinical Oncology 30 (15_suppl), 2076-2076 |
| Anaplastic oligodendroglial tumors: The Cleveland Clinic experience.
N Hashemi-Sadraei, L Robles Irizarry, M Patel, TM Tekautz, ES Murphy, … Journal of Clinical Oncology 30 (15_suppl), 2100-2100 |
| Low-grade gliomas in older patients.
AA Fawole, L Robles Irizarry, N Hashemi-Sadraei, M Patel, MS Ahluwalia Journal of Clinical Oncology 30 (15_suppl), 2093-2093 |
| Prognostic nomogram in elderly patients with glioblastoma.
M Patel, N Hashemi-Sadraei, P Elson, MS Ahluwalia Journal of Clinical Oncology 30 (15_suppl), 2096-2096 |
| Stereotactic radiosurgery of brain metastases in elderly patients: The Cleveland Clinic experience.
M Ahluwalia 15th Biennial Canadian Neuro-Oncology Meeting, |
| ELEVATED GLUCOSE LEVELS AND SURVIVAL IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
N Hashemi-Sadraei, H Bawa, G Rahmathulla, M Patel, P Elson, … NEURO-ONCOLOGY 13, 63-64 |
| MEDICAL AND NEURO-ONCOLOGY
G Prithviraj, S Sommers, R Jump, B Halmos, N DeVito, M Yu, R Chen, … Neuro-oncology 13 (Suppl 3), iii41-iii68 |
| Prognostic factors in elderly patients with grade 3 gliomas.
A Satra, N Hashemi-Sadraei, HS Bawa, DM Peereboom, G Stevens, … Journal of Clinical Oncology 29 (15_suppl), 2093-2093 |
| Prognostic factors in patients with WHO grade 3 gliomas: The Cleveland Clinic experience.
N Hashemi-Sadraei, HS Bawa, A Satra, G Rahmathulla, M Patel, … Journal of Clinical Oncology 29 (15_suppl), 2053-2053 |
| Glioblastoma in the elderly: The Cleveland Clinic experience (1992-2010).
HS Bawa, N Hashemi-Sadraei, JH Suh, G Stevens, G Rahmathulla, … Journal of Clinical Oncology 29 (15_suppl), 2066-2066 |
Articles 1–62
2025 Peter A. Winograd Endowed Professorship in Clinical Research, University of New Mexico Comprehensive Cancer Center
2024 Selected participant for Emerging Leaders: Changing the Face of Leadership, University of New Mexico and University of Southern California Norris Comprehensive cancer Centers
2024 Research Mentorship Excellence Award, for the support of the Hematology and Oncology ACGME fellowship for University of New Mexico Comprehensive Cancer Center, Albuquerque, NM
2021 Ian Rabinowitz Award for Teaching Excellence 2020-, for the support of the Hematology and Oncology ACGME fellowship for University of New Mexico, Comprehensive Cancer Center, Albuquerque, NM
2018 Selected participant for AACR/ASCO Vail Methods in Clinical Cancer Research Workshop, Vail, Colorado
2017 George and Sarah Jane Fisher Young Investigator Award A research grant awarded by Hoosier Cancer Research Network (HCRN), Indianapolis, IN
2015 Outstanding Graduating Resident of the Year, 2014-2015 (class of 36), University of Texas Health Science Center at Houston, Houston, TX
No videos found.
3686 S. Rome St.
Gilbert, AZ 85297
Hours:
Monday- Friday
8am-5pm
